From principle to practice: bridging the gap in patient profiling.
The standard clinical coagulation assays, activated partial thromboplastin time (aPTT) and prothrombin time (PT) cannot predict thrombotic or bleeding risk. Since thrombin generation is central to haemorrhage control and when unregulated, is the likely cause of thrombosis, thrombin generation assays (TGA) have gained acceptance as "global assays" of haemostasis. These assays generate an enormous amount of data including four key thrombin parameters (lag time, maximum rate, peak and total thrombin) that may change to varying degrees over time in longitudinal studies. Currently, each thrombin parameter is averaged and presented individually in a table, bar graph or box plot; no method exists to visualize comprehensive thrombin generation data over time. To address this need, we have created a method that visualizes all four thrombin parameters simultaneously and can be animated to evaluate how thrombin generation changes over time. This method uses all thrombin parameters to intrinsically rank individuals based on their haemostatic status. The thrombin generation parameters can be derived empirically using TGA or simulated using computational models (CM). To establish the utility and diverse applicability of our method we demonstrate how warfarin therapy (CM), factor VIII prophylaxis for haemophilia A (CM), and pregnancy (TGA) affects thrombin generation over time. The method is especially suited to evaluate an individual's thrombotic and bleeding risk during "normal" processes (e.g pregnancy or aging) or during therapeutic challenges to the haemostatic system. Ultimately, our method is designed to visualize individualized patient profiles which are becoming evermore important as personalized medicine strategies become routine clinical practice.
Department of Biochemistry, University of Vermont, Burlington, Vermont, United States of America.
Jonathan H
JH
Foley
Thomas
T
Orfeo
Anetta
A
Undas
Kelley C
KC
McLean
Ira M
IM
Bernstein
Georges-Etienne
GE
Rivard
Kenneth G
KG
Mann
Stephen J
SJ
Everse
Kathleen E
KE
Brummel-Ziedins
D000293:Adolescent; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000378:metabolism; D001777:Blood Coagulation / Q000187:drug effects; D003198:Computer Simulation; D005169:Factor VIII / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006467:Hemophilia A / Q000378:metabolism / Q000517:prevention & control; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D011247:Pregnancy; D011292:Premedication; D011486:Protein C / Q000378:metabolism; D013917:Thrombin / Q000378:metabolism*; D014859:Warfarin / Q000627:therapeutic use; D055815:Young Adult
D000925:Anticoagulants; D011486:Protein C; D014859:Warfarin; D005169:Factor VIII; D013917:Thrombin